EL7.AI
StocksUpdated•Originally published 6 April 2026•Updated 8 April 2026•
1 min read

uniQure (QURE) Faces Lawsuit Over Alleged Data Distortion and FDA Criticism

Key Facts

1Hagens Berman is updating its investigation into uniQure N.V. (QURE) following rebukes from the U.S. FDA.
2The investigation involves allegations of 'distorted' data and public criticism from FDA officials.
3A one-week deadline has been set for affected shareholders to contact the law firm.

A formal lawsuit has been filed against uniQure N.V. (QURE) following rebukes from officials at the U.S. FDA. The legal action centers on allegations that the company presented "distorted" or misleading clinical data to the public and its shareholders. Law firm Hagens Berman has established a specific deadline of April 13, 2026, for affected shareholders to join the lawsuit and participate in the legal proceedings. This escalation follows public criticism from FDA officials, which has raised significant concerns regarding the transparency of the company's reporting. These developments continue to place downward pressure on QURE stock as investors weigh the risks of litigation and potential legal costs. Analysts are closely monitoring the case's impact on the company's reputation and its ability to secure future regulatory approvals.